• Recent passage of 2018 Farm Bill clears way for farming of industrial hemp and production of cannabidiol (CBD)
• Photobioreactors currently used in cultivation of green algae, a high protein dietary supplement or whole food cultivated worldwide with multiple industry uses
• Project goal includes mass production of CBD from cell cultures of industrial hemp
• SinglePoint’s online CBD distribution subsidiary, SingleSeed, poised for significant growth as selection of CBD products increases in 2019
• Hemp-derived CBD market expected to reach $1.3 billion by 2022

SinglePoint, Inc. (OTCQB: SING), a fully reporting technology company providing mobile payments, blockchain solutions and ancillary cannabis services, is quickly taking advantage of its first-mover status in the CBD space with an investment in TorusMed Inc., which plans to develop CBD cell cultures from industrial hemp with photobioreactors. In a news release announcing the investment, SinglePoint said that the project’s goal is to ultimately have pharmaceutical grade CBD cultivated in a lab setting to ensure consistency of a premium product (http://ibn.fm/PUg9g).

Photobioreactors create a closed system, providing a controlled environment fed by either natural sunlight or artificial light that enables high productivity of plant cell structures. Photobioreactor systems are currently being used to produce algae, which has emerged as a popular element in industries like cosmetics, pharmaceuticals, food and beverage, biofuels, pollution control and more (http://ibn.fm/81jiv).

The recent passage of the 2018 Farm Bill, which legalized industrial hemp and removed it from the Controlled Substance Act, is good news for anyone interested in hemp, the THC-free strain of cannabis whose uses range from fibers to food to pharmaceuticals. A recent episode of Science Friday with Ira Flatow focused on farming the plant and the medical research underway studying the potential uses of CBD derived from hemp (http://ibn.fm/c51z3).

“Well, I just think that CBD is really exceptional,” Flatow’s guest, Dr. Esther Blessing, a researcher and assistant professor of psychiatry at NYU Langone Health in New York City, stated in the interview. “There’s been no other drug in the history of neuropsychiatry that has the potential to treat so many different disorders. I’m not saying that it does treat them all, but the evidence is good so far. So, it would be ideal to put aside all of these issues of legality and the fact that it comes from the cannabis plant and start to be able to treat it as a medicinal agent with controlled clinical trials and get it out to people who need it as quickly as possible.”

Teaming up with TorusMed in a project to mass cultivate CBD cell cultures using photobioreactors makes sense for SinglePoint on multiple levels. Development of pharmaceutical grade CBD that is cultivated in lab settings could potentially change the way industrial hemp and CBD are manufactured by reducing time, cost and resources while increasing consistency, safety and scalability. The project’s specific aim is to develop optimal protocols for mass CBD production from cell cultures of industrial hemp. Photobioreactors offer several advantages as compared to open-field farm cultivation, including, but not limited to, independence from weather and seasonal climatic conditions and scalable industrial and environmentally-controlled production.

SinglePoint plans to distribute the premium CBD upon completion of the development, and it is currently working with producers and manufacturers for distribution of industrial hemp CBD through its ecommerce site, SingleSeed.com. SinglePoint intends to increase revenue and sales through the subsidiary by growing its distribution to both retail and other channels.

For more information, visit the company’s website at www.SinglePoint.com

• Global market for energy-efficient buildings, products trending upward amid growing attention to climate change concerns
• Zenergy’s flagship Zero Cost Program largely responsible for company’s million-dollar year-over-year revenue growth as an energy efficiency technology provider
• Company drawing on $1.6 million in new funding with potential for up to $10 million as it advances Zero Cost Program, plans energy commodity sales

Energy consumers’ ability to efficiently manage their usage is beginning to acquire the same importance as other environmental impact and pollution reduction concerns, and next-generation energy utility companies such as Zenergy Brands, Inc. (OTC: ZNGY) are working to make a better world possible.

For years, the science community has expressed interest in evidence of changes to the earth’s climate on a significant scale. Media reports have advanced warnings about potential long-term consequences on human, plant and animal life resulting from trending changes in global surface temperature, exemplified by sizeable glacial melting at the earth’s poles (http://ibn.fm/PDsB9), an increasing severity of extreme weather conditions (http://ibn.fm/ULNTH) and rising sea levels flooding coastal real estate (http://ibn.fm/Ndd48).

An increase in greenhouse gases such as carbon dioxide, methane, nitrous oxide and fluorocarbons attributed mainly to humanity’s pollutants – particularly burned fossil fuels – gets the blame for the changing climates. Many activists have spurred governmental policies that favor pollutant reduction, such as the elimination of chlorofluorocarbons emitted into the atmosphere and the multi-national signing of the Paris Agreement accords that call for more electric vehicles to replace petroleum-fueled cars (http://ibn.fm/rmaiW).

Zenergy’s virtual utility model promotes the smart use of utilities to reduce energy consumption by eliminating wasteful behaviors. The company’s flagship technological offering, the Zero Cost Program, employs a Managed Energy Services Agreement (MESA) to deliver conservation solutions for water, gas and electrical utilities. Under the MESA, Zenergy assumes the responsibility for upfront costs related to putting the necessary equipment retrofits in place or even building them into a new structure to suit the client. The customers then pay a downward scaling part of their utility expense savings to Zenergy over the term of the contract before deciding whether to renew the contract every five to seven years.

The Zero Cost Programs’s energy-saving solutions include HVAC and refrigeration motor controllers, load factor technologies, building-envelope-based technologies, weatherization-based technologies, remote access to smart controls and LED lighting. The program is designed to reduce utility consumption by 20 to 60 percent through remote access and artificial intelligence devices for residential, commercial, industrial and municipal end-use customers alike.

As consumer awareness of climate change-related problems grows, the global market for energy-efficient building solutions is expected to increase to nearly $360.6 billion by 2026 from 2017’s reported $227.4 billion, according to a report by Navigant Research (http://ibn.fm/hpl2Y). Likewise, the energy efficient devices market is expected to grow to $908.49 billion by 2022 (http://ibn.fm/RsRMe).

The dawn of 2019 heralds a year of potential for Zenergy as it works to take advantage of a recent agreement with a fund management group. This will establish a $10 million debenture facility that provides an initial tranche of funding of $1.6 million and the remainder over the course of the arrangement through June 2021, if the lender approves it as a result of the company’s performance (http://ibn.fm/FFVtT). The company also intends to provide an in-house clientele for its Zero Cost Program by rebounding from a canceled Texas retail electric provider (REP) acquisition and re-entering the commodity sales business sometime after June as a strictly B2B platform with a new wholesale energy distribution partner, according to a statement by CEO Alex Rodriguez issued on January 7 (http://ibn.fm/oGjNc).

Zenergy’s revenues topped $1.2 million at the close of the third quarter, primarily as a result of the Zero Cost Program, according to the company’s most recent 10-Q filing, marking an exponential rise from $23,585 of the prior year (http://ibn.fm/E8kvq).

For more information, visit the company’s website at www.ZenergyBrands.com

• Supreme Cannabis recently provided a 7ACRES construction update, announcing that 19 flowering rooms have been completed and the remaining six are expected to be ready by March 2019
• The modular design of the facility enables independent adjustment of crop cultivation conditions, resulting in higher quality and better yield
• According to Supreme Cannabis, 7ACRES’ production capacity will reach 50,000 kilograms by mid-2019

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) (FRA: 53S1) recently announced that it has completed 19 of the 7ACRES flowering rooms and is on target to complete all 25 by March 2019. Once construction is finalized, 7ACRES will have a greenhouse footprint of nearly 300,000 square feet (http://ibn.fm/HkxFO).

Under the updated timeline provided by Supreme Cannabis, three additional flowering rooms will become operational in January, and, following completion of all 25 flowering rooms in March, the primary office and administrative areas will be finalized by the end of the first half of 2019.

The estimated annual output of Supreme Cannabis Company’s flagship brand and wholly owned subsidiary 7ACRES is on pace to reach 50,000 kilograms by mid-2019. The addition of the greenhouse flowering rooms will increase the total size of the facility to 440,000 square feet.

According to the Supreme Cannabis management team, 7ACRES is a unique facility for Canada, with an unparalleled ability to produce high-quality cannabis on a commercial scale and each flowering room utilizing sophisticated HPS lighting technology to ensure the quality of indoor lighting. The additional lights are supplementary to the sunlight entering the flowering rooms and are needed to improve terpene and cannabinoid production.

7ACRES is characterized by the modular design of each of the flowering rooms. As a result, the environmental conditions in each room can be adjusted independently of the other facility modules. The risk of losses is reduced exponentially through tailored cultivation conditions that are precisely chosen for each crop.

Any expansion of the facility is the subject of Health Canada regulatory approval. Upon completion of the flowering rooms, Supreme Cannabis plans to streamline the Health Canada review by submitting multiple rooms for simultaneous review.

“7ACRES sets the international standard for cannabis cultivation and allows us to grow craft-quality cannabis at scale,” Supreme Cannabis president and Founder John Fowler said in a news release. “We believe consumer behaviour has validated our thesis that people prefer higher-quality flower and are willing to pay more for it, and as the market expands for derivative products such as vape pens and edibles we expect consumers will prefer products extracted from the highest quality inputs.”

7ACRES is a cultivation facility that ranks among the first 40 federally licensed cannabis producers in Canada. Through a focus on scaled cannabis production, 7ACRES will enjoy a high level of flexibility as the Canadian market continues to grow.

The quality of 7ACRES’ production is one of its primary strengths, as Supreme Cannabis has noted. This high level of quality was officially recognized when 7ACRES received a ‘Brand of the Year’ award in 2018 at the Canadian Cannabis Awards (http://ibn.fm/OzjqI).

Supreme Cannabis is a Canadian publicly-traded company committed to providing premium brands and products. Its portfolio includes the wholly owned 7ACRES subsidiary, an equity investment and a long-term global distribution partnership with Lesotho-based Medigrow.

For more information, visit the company’s website at www.Supreme.ca

• Spectrum Global Solutions specializes in telecommunications via its subsidiaries
• The company engineers, upgrades, installs and maintains next-generation telecommunication networks
• Its growth strategy includes acquisitions, increasing market share and leveraging organic revenue and margin growth

Spectrum Global Solutions, Inc. (OTC: SGSI) is the holding company for next generation technology companies that specialize in telecommunications throughout the United States, Canada and the Caribbean. Via its subsidiaries, the company provides services directly to carriers, aggregators, utilities, enterprise clients, project management organizations (PMO) and original equipment manufacturers (OEM). Spectrum is one of the few engineering and installation companies that can provide all services and bundle products for telecommunications clients. Spectrum Global Solutions is headquartered in Longwood, Florida.

The company is a foremost single-source provider of end-to-end, next-generation wireless and wireline network infrastructure and professional service solutions. Its subsidiaries include AW Solutions, Inc. – Telecommunications & Engineering Services; AW Solutions Puerto Rico -Telecommunications & Engineering Services; and Tropical Communications, Inc. – Utilities. In addition, its subsidiaries include ADEX Corporation – Professional Services & Solutions, and ADEX Puerto Rico, LLC – Professional Services & Solutions.

Fundamentally, Spectrum Global Solutions engineers, upgrades, installs and maintains next-generation telecommunications networks. The company is professionally registered in 49 states, three U.S. territories (Puerto Rico, U.S. Virgin Islands and Guam) and six Canadian Provinces. Its services run the gamut from a single activity to multi-year, multi-region large scale turnkey development contracts (http://ibn.fm/s7kd2).

A projected $157 billion in U.S. telecommunication carrier capital expenditures is expected by 2021, and 5G next generation networks will be a significant part of this expenditure (http://ibn.fm/VXCUE). Spectrum Global Solutions is positioned to take advantage of this development because of its acquisitions and its experience in completing greater than 150,000 project activities on wireless, DAS, wireline and fiber networks throughout the U.S. The company’s ADEX Corp. and ADEX Puerto Rico LLC acquisitions have set Spectrum on course to benefit from the ongoing rollout of 5G services during the coming years (http://ibn.fm/wmMRA). Information Age (http://ibn.fm/OoYa6) notes that, “Not only does 5G promise to boost efficiency and unleash the potential of automation, but it will also enable us to explore developing technologies such as virtual reality (VR) and augmented reality (AR).”

A proven market operator in a high-growth telecom market segment, Spectrum Global Solutions’ growth strategy includes strategic and tactical acquisitions. Its criteria for acquisitions focus on companies with synergistic strategic value, a history of profitability and operations that are accretive to earnings and growth. Criteria also includes companies with strong management/retention, long-term customer relationships and sufficient size to add scale (http://ibn.fm/nfbOK).

The company’s growth strategy also aims to build market share and leverage organic revenue and margin growth. This involves focusing its sales team at new service provider targets, growing corporate margins and establishing new PMO and OEM partnerships. This strategy also aims to expand SGSI’s service footprint and open the door for new services, as well as maximizing cross-selling opportunities by taking advantage of its operating subsidiaries’ clients, services and relationships.

Spectrum Global Solutions, with its experienced management team, has the initiatives in place to foster shareholder growth. With client re-engagements at more than 98 percent, the company’s track record speaks for itself. Spectrum Global Solutions is ready to facilitate 5G growth as it continues to provide premier telecommunications engineering and infrastructure services to its diverse clientele.

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

• Supreme Cannabis Company focuses on growing sustainable cannabis businesses
• The company’s portfolio includes innovative 7ACRES brand
• Supreme Cannabis recently signed an agreement with Wiz Khalifa’s Khalifa Kush Enterprises

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) (FRA: 53S1) works to identify new opportunities to build unique cannabis businesses. The company’s 7ACRES licensed producer subsidiary operates a 440,000 sq. ft. facility in Ontario, Canada. 7ACRES’ specialty is growing high-quality cannabis in large quantities. Supreme Cannabis Company has its corporate headquarters in Toronto, Ontario.

Supreme Cannabis’ portfolio additionally includes an equity investment and long-term worldwide distribution partnership with Medigrow. This partnership is for the export of medical-grade cannabis oil. Moreover, Supreme Cannabis has partnered with a number of Canadian cannabis retailers to advance its distribution in the medical cannabis market.

7ACRES is the company’s flagship brand (http://ibn.fm/43RME). 7ACRES’ hybrid greenhouse is in Kincardine, Ontario (http://ibn.fm/YiNzO). At this facility, indoor-quality buds are produced with sun-grown characteristics. Using the full-spectrum sun, 7ACRES is the largest facility of its kind to grow with advanced HVAC and CO2 enrichment. At present, the capacity at the facility is 13,333 kilograms of dried cannabis per year. Supreme Cannabis plans to boost production by mid-2019 to a rate of 50,000 kilograms annually.

Recently, Supreme Cannabis announced an exclusive consulting agreement with Wiz Khalifa’s Khalifa Kush Enterprises (KKE). This agreement is geared toward developing and launching a line of premium cannabis products under the KKE brand into the emerging Canadian marketplace (http://ibn.fm/PSzxC). Supreme Cannabis Company’s consulting services agreement is with Khalifa Kush Enterprises Canada ULC, which is an affiliate of KKE in the U.S.

Wiz Khalifa is a Grammy Award-winning American musician and actor. He has become an icon in the cannabis community through the development of his line of regulated marijuana strains, products and concentrates under the Khalifa Kush brand. He has focused on raising awareness for the cannabis industry. In a news release, Khalifa, principal of KKE, said, “My team and I have spent the past year finding a partner that shares our vision, values, and passion for cannabis. The team at Supreme Cannabis understands the importance of high quality cannabis and how to produce [it at scale].”

Supreme Cannabis will have exclusive rights to the KKE brand within Canada. It will also have exclusive rights to potential expansion into global markets. This will depend on approval from KKE, as well as the legal status of the products in international markets. Supreme Cannabis Company President John Fowler added, “I was impressed by the quality of the ‘Khalifa Kush’ strain and the level of care and involvement Wiz had with developing the strain and working with cultivators to continue to improve quality batch-by-batch. We’re excited to be working with KKE Canada to build out another brand with the same commitment to quality.”

At the center of the cannabis space since 2014, Supreme Cannabis Company’s mission is to grow sustainable cannabis businesses. The company offers investors potential returns from the Canadian market and, in the future, beyond. As it continues to identify opportunities to build groundbreaking cannabis businesses worldwide, Supreme Cannabis is positioned at the forefront of the industry.

For more information, visit the company’s website at www.Supreme.ca

• Vinay Tolia, co-CEO of Flowr, sees the move as giving the company exposure to European and Australian markets
• The company believes that the combination of its cultivation expertise with Holigen’s development of large-scale cannabis facilities could result in one of the lowest-cost producers worldwide
• Clarus Securities has initiated coverage on FLWR stock with a ‘speculative buy’ rating and a one-year price target of $5; its research report projects adjusted EBITDA of C$6.8 million in FY2019

The Flowr Corporation’s (TSX.V: FLWR) (OTC: FLWPF) acquisition of 19.8 percent of Holigen Limited for a cash payment of C$6 million and the signing of an intellectual property sharing agreement is expected to have far-reaching benefits for the company. Flowr says that it will result in an acceleration of Holigen’s projects, including an outdoor cultivation license on a seven million square foot site in Portugal with the potential to produce 500,000 kg of cannabis products annually (http://ibn.fm/hIlOQ).

Flowr, through its subsidiaries, is a vertically integrated Canadian cannabis company and licensed producer that focuses on non-irradiated premium flower production. Its headquarters are in Markham, Ontario; and its production facilities are in Kelowna, British Columbia. Using its patented growing systems, it conducts large-scale cultivation operations built to Good Manufacturing Practice (GMP) standards. It is also well positioned to serve the adult use market with a line of premium cannabis products.

Based in Portugal and Australia, Holigen is forming partnerships with cannabis distributors in Germany, Poland, the United Kingdom and Ireland. It also has strong ties to the largest medical cannabis distributor in Australia. The company is in the final stages of obtaining a license to export cannabis from Portugal, giving it potential direct marketing access to the European Union and other global markets.

“We believe this is a transformative transaction that establishes Flowr as a global player in the cannabis industry,” CEO Vinay Tolia of Flowr stated in a news release. “We’re using our financial strength and industry-leading cultivation expertise to gain exposure to the rapidly expanding European and Australian markets through Holigen.”

FLWR is focused on high-yield production and believes that Holigen’s outdoor production site in Portugal could offer one of the lowest cost cannabis cultivation opportunities globally, given Portugal’s ideal climate and relatively low land and labor expenses, as well as Flowr’s cultivation expertise. Holigen is currently developing four cultivation facilities in Portugal and Australia along with production and research and development sites.

Holigen expects to complete licensing for its first site in Portugal by the middle of 2019 and plans to be one of the few licensed companies in Europe producing products in GMP-compliant facilities.

Flowr is receiving coverage from Clarus Securities. In a research note to investors, Noel Atkinson, analyst at Clarus, projects that Flowr will grow to adjusted EBITDA of C$6.8 million in FY2019, as he stated in the Cantech Letter (http://ibn.fm/4ZeJ7).

For more information, visit the company’s website at www.Flowr.ca

• In December 2018, Plus Products finalized the acquisition of GOOD CO-OP to further cement its leadership position within the California cannabis-infused edibles field
• Through the acquisition, Plus will gain quick access to the baked edibles market – one of the most rapidly growing niches in the space
• The CAGR of cannabis-infused baked goods for the coming five years is forecast at 14.12 percent, and the overall edibles market is expected to exceed $3 billion

Plus Products Inc. (CSE: PLUS) announced in December 2018 that it had finalized the acquisition of GOOD CO-OP Inc. – a California-based cannabis-infused baked goods brand. This acquisition is expected to enable Plus to solidify its top position in the edibles field (http://ibn.fm/B7bwv).

The acquisition is valued at approximately C$2.03 million and will be satisfied through the issuance of 357,464 restricted subordinate voting shares of Plus.

Currently, Plus ranks as the leading edibles brand in California, and its primary focus is within one of the largest edibles categories – gummies. Through the acquisition of GOOD CO-OP, Plus gains a strategic advantage in that it can enter a second rapidly-growing category, that of baked goods.

In 2018, the baked goods category accounted for approximately 13 percent of the cannabis-infused edibles market. Cannabis-infused edibles represent the most rapidly-evolving product category in the cannabis field. The market is projected to reach volumes ranging from $3 billion-$5 billion in the next five years, which would represent an overall increase of 130 percent (http://ibn.fm/llF3W).

The five-year CAGR of baked goods is one of the highest in the industry at 14.12 percent. Sugar candies and gummies are also projected to grow significantly over the coming five years, at a CAGR of 15.94 percent.

Plus Products already has a well-established market position that could promote fast growth in the years to come. In Q3 2018, the company ranked as the number one edible brand in California (http://ibn.fm/D3sca). According to the ranking, the two best-selling branded products are PLUS Sour Watermelon Gummies and PLUS Blackberry and Lemon Gummies, according to BDS Analytics and Headset retail sales data analysis. These two products have scored top positions across all categories in California, including flower, vaporizer, edible and topical products.

“We grew PLUS into the top edibles company in California by leading with our product. We have focused on manufacturing consistent, high quality edibles that resonate with consumers,” Plus CEO Jake Heimark said in a news release. The year of 2018 was a big one for Plus, and the company continues to strive to expand its portfolio and broaden its geographic reach moving forward, Heimark added.

In his words, the acquisition of GOOD CO-OP accelerates the company’s entry into the baked edibles field. It will help solidify the company’s market position even further. According to Heimark, Plus is committed to becoming the largest edibles brand across all legal jurisdictions.

GOOD CO-OP is a premium edibles brand that focuses predominantly on the creation of delicious cannabis-infused brownies and other baked goods. Taste and flavor profiles are two of the brand’s primary concerns, which is why GOOD CO-OP does not use additives or preservatives.

The GOOD CO-OP product portfolio includes bite-size brownies and pumpkin spice blondies, among other products. These have been featured in various reputable media like Vice Magazine, Fortune and Eater.

For more information, visit the company’s website at www.PlusProducts.com

• Development of frozen formulation of Bria-IMT completed for on-demand shipment to clinical sites
• Novel formulation is easily transportable to distant locations, easy to use, safe and has improved potency; it accommodates higher patient volumes at reduced per-dose costs
• Promising novel immunotherapy technology provides hope to patients with advanced breast cancer
• Breast cancer remains the leading cancer diagnosed in women and the second-most common cancer overall

Immuno-oncology focused biotechnology company, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) recently announced the imminent clinical use of a novel, frozen formulation of Bria-IMT, the company’s lead cancer drug candidate targeting the unmet medical needs of advanced breast cancer patients. Comprehensive data analysis is underway following completion of a Phase I/IIa clinical trial of Bria-IMT in a combination study with pembrolizumab – marketed as KEYTRUDA® by Merck & Co., Inc. (NYSE: MRK) – and listed on ClinicalTrials.gov as NCT03328026.

The company’s frozen formulation allows for the storage of cryopreserved, ready-to-inject Bria-IMT for cold-chain overnight transport to clinical sites where it will be thawed prior to injection in patients. This unique formulation of Bria-IMT has also shown improved potency compared to the old formulation in vitro. Long term, this novel, frozen formulation is expected to carry reduced per-dose costs compared to the old formulation, the company stated in a news release (http://ibn.fm/qHd1W). Bria-IMT activates the immune system to destroy cancer cells in a way that’s believed to be both unique and more effective than other, similar approaches. The frozen formulation will also be applicable to Bria-OTS, BriaCell’s personalized off-the-shelf immunotherapy, which is being developed.

“Currently, the old formulation of Bria-IMT used in the clinical trials was cumbersome to prepare, as it had to be processed the day before administration to patients. This created a great deal of inconvenience and complexities for the manufacturer, clinicians and patients,” Dr. Bill Williams, BriaCell’s president and CEO, said in a news release. “The new frozen formulation has shown improved potency and stability in vitro and, based on its constituents and injection route, is expected to be highly bioavailable. This enhances Bria-IMT’s potential to address patient needs as a ready-to-use treatment alternative that can be prepared in advance, is easily transportable to distant locations in large quantities, is easy to use, and is safe and highly effective.”

Cryopreservation is a process that preserves organelles, cells, tissues or any other biological constructs by cooling the samples to very low temperatures. The successful cryopreservation of cells and tissues is the subject of intensive research for many medical applications, as noted in a scholarly article (“Cryopreservation and its clinical applications”) published online by the National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health (http://ibn.fm/vdD5Y).

“We are excited to add this novel technology to our growing immunotherapy franchise as we advance safe and effective treatment solutions for advanced breast cancer, an unmet medical need,” Williams continued. “We look forward to the efficacy data of our ongoing clinical trial, which will provide further evidence for this promising novel therapy to bring hope to patients with advanced breast cancer.”

Breast cancer is the most commonly occurring cancer in women and the second-most common cancer overall, with over two million new cases diagnosed worldwide in 2018, according to the World Cancer Research Fund International (http://ibn.fm/bvFox). Research into powerful immunotherapies for cancer, also known as immune-oncology, is growing, the Cancer Research Institute (“CRI”) noted in an article highlighting a robust international interest in the field (http://ibn.fm/huQb5). The article, titled “Trends in the global immune-oncology landscape,” appeared online in Nature Reviews Drug Discovery from Nature Publishing Group.

“The quantitative analyses from this report reveal a 67 percent increase of the number of active immuno-oncology pipeline agents in a year, showing the unprecedented enthusiasm and commitment of the field,” said Jill O’Donnell-Tormey, Ph.D., chief executive officer and director of scientific affairs at the Cancer Research Institute.

Cancer care affects not just the patient, but caregivers as well, with many concerned about the financial impact and availability of care near where they live, as the American Society of Clinical Oncology (ASCO) noted in its second annual National Cancer Opinion Survey (http://ibn.fm/wlm4g). Bria-Cell’s frozen formulation of its lead cancer drug candidate, Bria-IMT, importantly offers the ability to easily transport the cryopreserved formulation anywhere it is most needed and at an expected reduced per-dose cost.

“Patients are right to be concerned about the financial impact of a cancer diagnosis on their families. It’s clear that high treatment costs are taking a serious toll not only on patients, but also on the people who care for them,” added ASCO Chief Medical Officer Richard L. Schilsky, MD, FACP, FASCO. “If a family member has been diagnosed with cancer, the sole focus should be helping them get well. Instead, Americans are worrying about affording treatment, and in many cases, they’re making serious personal sacrifices to help pay for their loved ones’ care.”

BriaCell Therapeutics Corp. will present a poster at a 2019 Keystone Symposia scientific conference being held on January 20-24, 2019, at Fairmont Hotel Vancouver in Vancouver, British Columbia. The poster will highlight BriaCell’s recent clinical and research-focused development of Bria-IMT and BriaDX, the corresponding companion diagnostic test, which helps identify those patients most likely to benefit from Bria-IMT, as well as Bria-OTS, the first off-the-shelf personalized treatment for advanced stage breast cancer.

BriaCell management will also attend Biotech Showcase 2019, an important investor conference taking place on January 7-9, 2019, at Hilton San Francisco Union Square in San Francisco, California.

For more information, visit the company’s website at www.BriaCell.com

• As the 2018 Federal Farm Bill legalizes hemp across the U.S., SinglePoint prepares for rapid growth in 2019
• The company is working on development programs and potential acquisitions in order to establish its leading industry position
• Through hemp legalization, the industry is expected to grow exponentially in the years to come, reaching a volume of $20 billion by 2022

Congressional approval of the 2018 Federal Farm Bill that removes hemp production from federal prohibition is expected to create amazing new opportunities for industry representatives in 2019 and beyond. SinglePoint, Inc. (OTCQB: SING) released an official statement underlining that the legislative change will provide a huge chance for growth for the company via subsidiary SingleSeed (www.SingleSeed.com) – an ecommerce seller and distributor of industrial hemp-based CBD products (http://ibn.fm/ruZvq).

The mainstream approval of hemp and it turning into a federally legal commodity will enable the company to expand its portfolio and add more offerings. Industrial hemp now has an opportunity to be competitive in the global marketplace, SinglePoint’s statement reads.

In addition, SinglePoint is currently negotiating potential acquisitions across different sectors, the company announced. Through its acquisition model, SinglePoint expects to continue growing revenue in 2019. The company was among several companies positioned to capitalize on the legislation measures and continue growing, according to InvestorIdeas.com, a leading investor news resource covering hemp and cannabis stocks in a 2019 outlook for the sector (http://ibn.fm/ovsY1).

SinglePoint is exploring opportunities to produce industrial hemp through joint ventures with leading industry representatives. Investment and development programs are also under consideration. Through such programs, strains of CBD extracted from hemp will be grown in a photobioreactor for the purpose of making the process faster and more cost-efficient.

According to company CEO Greg Lambrecht, SinglePoint is working to become a key player in the distribution and sourcing of the best hemp products on the market. The company’s managerial team is confident that the current business model and the planned expansions will contribute to its sustainable growth and reputation establishment efforts in 2019.

The Federal Farm Bill was ratified by President Donald Trump on December 20, 2018. As a result, hemp is no longer considered a schedule one substance. Before the passing of the bill, hemp production in the U.S. was mostly limited. The legislative change that turns hemp into a lawful agricultural commodity is expected to contribute to exceptionally rapid growth in the field.

According to some forecasts, the industry could top $20 billion by 2022 (http://ibn.fm/dNr3f). Right now, the largest share of the hemp market is formed by CBD products, and their dominance will likely remain unchanged. Investor interest in the sector is expected to grow rapidly once hemp production goes outside the realm of pilot programs and research initiatives.

Since hemp is now legal in all 50 states, experts predict that 2019 is going to be the ‘year of CBD’ (http://ibn.fm/ju0TI). In 2018 alone, the U.S. saw an 80 percent increase of the CBD market. The growth was fueled mainly by small and medium-sized retailers. The Federal Farm Bill could now turn the attention of much larger entities toward the industry, contributing to more rapid growth in the years to come.

SinglePoint specializes in the acquisition of small and medium-sized companies with an emphasis on new technologies. The company enables investors to make investments across a wide range of assets, including blockchain, cryptocurrency applications and cannabis, among others.

For more information, visit the company’s website at www.SinglePoint.com

• Canadian cannabis market set for CAGR of 77.9 percent to 2021
• Icon’s Vertical integration strategy could capture high margins
• Company will have operations in cultivation, extraction and retail

The legalization of recreational cannabis in Canada has made analysts project rapid growth for the industry. Spending on adult-use marijuana (http://ibn.fm/BtVkp) is “estimated to reach over $3 billion in 2021, driving a CAGR of 77.9 percent from 2018-2021.” Eventually, Canada’s legal cannabis market will likely be comparable in size to the hard liquor or wine market. Growing organically, some sectors will be profitable (others, perhaps, less so), but telling which may not be so easy. Consequently, the vertical integration strategy that Icon Exploration Inc. (TSX.V: IEX.H) is employing, by straddling the value chain, seems best for capturing the highest margins. The company will have a finger in many pies. It has been stocking up on talent as it prepares to commence operations in cannabis cultivation, refining and extraction and retail.

Even before the legalization of recreational cannabis on October 17, 2018, the cannabis market in Canada had been growing at a healthy clip. The number of medical marijuana patients has been increasing by 10 percent monthly, sales of dried cannabis have risen at six percent monthly and the sale of cannabis oil has increased by 16 percent monthly. In 2017, about 4.9 million Canadians aged 15 to 64 spent an estimated $5.7 billion on cannabis for medical and non-medical purposes. This is equivalent to about $1,200 per cannabis consumer. In this lucrative market, Icon’s primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry.

The company is close to completing its acquisition of City View Green (CVG), a vertically integrated cannabis company. CVG has submitted an application to Health Canada for an Access to Cannabis for Medical Purposes Regulations (ACMPR) license, which is now at the in-depth review stage of the licensing process. CVG plans to develop a 40,000-square-foot growing facility near Toronto, about half of which will be converted into a modern greenhouse. The facility will have state-of-the-art LED lighting, HVAC and dehumidification systems and automation technologies designed to optimize the quality, safety and consistency of cannabis production.

A further 4,000 square feet will be used to house an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process, with plans to include ethanol extraction technology in the future. Another 4.3 acres remain available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.

Icon has been acquiring top talent, as well. Its management team now includes a master grower with cannabis-industry experience to manage indoor grow operations, as well as an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. In addition, negotiations are currently in progress with a private company that is seeking 37 retail cannabis licenses in Alberta, Canada, and discussions with various entities in Europe are also underway to arrange an off-take agreement for CBD oils and extracts.

For more information, visit the company’s website at www.IconExploration.net